Surgical treatment for primary chest wall sarcoma: a single-institution study

2019 ◽  
Author(s):  
T Stork ◽  
D Stefani ◽  
T Plönes ◽  
K Mardanzai ◽  
D Valdivia ◽  
...  
2021 ◽  
Vol 260 ◽  
pp. 149-154
Author(s):  
Stéphane Collaud ◽  
Theresa Stork ◽  
Uta Dirksen ◽  
Christoph Pöttgen ◽  
Balazs Hegedüs ◽  
...  

2011 ◽  
Vol 58 (10) ◽  
pp. 827-833 ◽  
Author(s):  
Jae Hyun Park ◽  
Sang-Wook Kang ◽  
Jong Ju Jeong ◽  
Kee-Hyun Nam ◽  
Hang Seok Chang ◽  
...  

2020 ◽  
Vol 73 (8) ◽  
pp. 1448-1455 ◽  
Author(s):  
T.P. Crowley ◽  
K. Atkinson ◽  
C.D. Bayliss ◽  
S. Barnard ◽  
R.H. Milner ◽  
...  

Clinics ◽  
2011 ◽  
Vol 66 (3) ◽  
pp. 501-503 ◽  
Author(s):  
Daniel Reis Waisberg ◽  
Fernando Conrado Abrão ◽  
Angelo Fernandez ◽  
Ricardo Mingarini Terra ◽  
Paulo Manuel Pêgo-Fernandes ◽  
...  

1963 ◽  
Vol 46 (2) ◽  
pp. 242-251 ◽  
Author(s):  
Eugene C. Weinstein ◽  
W. Spencer Payne ◽  
Edward H. Soule

2019 ◽  
Vol 23 (3) ◽  
pp. 240
Author(s):  
Juan Glinka ◽  
Rodrigo Sanchez Claria ◽  
Victoria Ardiles ◽  
Eduardo de Santibañes ◽  
Juan Pekolj ◽  
...  

Author(s):  
Na Rae Choi ◽  
Jung Han Lee ◽  
Jin Young Park ◽  
Dae Seok Hwang

The purpose of this study was to confirm the success rate of surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in patients at a single institution (Association of Oral and Maxillofacial Surgery (AAOMS) stages 1, 2, or 3), and to identify the factors that influence treatment outcomes. As a result of analyzing the outcomes of treatment, surgical “success” was achieved in 93.97% (109) of cases, and “failure” was observed at 6.03% (7) cases. Analysis of patient factors that potentially affect treatment outcomes showed that zoledronate dose (p = 0.005) and the IV (intravenous) injection of drugs (p = 0.044) had significant negative impacts.


Sign in / Sign up

Export Citation Format

Share Document